The Five-year Loss for Guanhao BiotechLtd (SZSE:300238) Shareholders Likely Driven by Its Shrinking Earnings
The Five-year Loss for Guanhao BiotechLtd (SZSE:300238) Shareholders Likely Driven by Its Shrinking Earnings
It is a pleasure to report that the Guanhao Biotech Co.,Ltd. (SZSE:300238) is up 72% in the last quarter. But if you look at the last five years the returns have not been good. In fact, the share price is down 29%, which falls well short of the return you could get by buying an index fund.
非常高興地報告,冠昊生物股份有限公司(SZSE:300238)在上個季度上漲了72%。但如果您看過去五年的情況,回報並不理想。事實上,股價下跌了29%,遠低於購買指數基金可以獲得的回報。
Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline.
雖然過去一週股東的投資回報率有所緩解,但在過去五年中仍處於虧損狀態,因此讓我們看看這家公司的基本業務是否是導致下跌的原因。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
禾倫·巴菲特在他的論文《格雷厄姆-道德斯維爾的超級投資者》中描述了股票價格並不總是合理地反映企業的價值。通過比較每股收益(EPS)和股價隨時間變化的變化,我們可以了解到投資者對某家公司的態度如何隨時間而變化。
During five years of share price growth, Guanhao BiotechLtd moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down. Other metrics may better explain the share price move.
在五年的股價增長中,冠昊生物股份有限公司從虧損轉爲盈利。這通常被認爲是積極的,因此我們對股價下跌感到驚訝。其他指標可能更好地解釋股價的變動。
Arguably, the revenue drop of 4.0% a year for half a decade suggests that the company can't grow in the long term. That could explain the weak share price.
可以說,半個十年每年營業收入下降4.0%,表明該公司長期無法增長。這可能解釋了股價疲弱的原因。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
你可以在這個免費的互動圖表中看到它的資產負債表如何隨着時間的推移而加強(或削弱)。
A Different Perspective
不同的觀點
It's good to see that Guanhao BiotechLtd has rewarded shareholders with a total shareholder return of 14% in the last twelve months. Notably the five-year annualised TSR loss of 5% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It's always interesting to track share price performance over the longer term. But to understand Guanhao BiotechLtd better, we need to consider many other factors. Even so, be aware that Guanhao BiotechLtd is showing 1 warning sign in our investment analysis , you should know about...
很高興看到冠昊生物股份有限公司在過去12個月內以14%的股東回報獎勵股東。值得注意的是,過去五年年化的TSR每年虧損5%,與最近的股價表現相比非常不利。我們通常更看重長期表現,而不是短期表現,但最近的改善可能暗示着業務內的(積極)拐點。跟蹤股價表現長期來看總是很有趣。但要更好地了解冠昊生物股份有限公司,我們需要考慮許多其他因素。即便如此,請注意,我們的投資分析中冠昊生物股份有限公司顯示出1個警告信號,您應該知道...
We will like Guanhao BiotechLtd better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我們看到一些內部大規模買入,我們將更喜歡冠昊生物股份有限公司。當我們等待時,請查看這份免費的低估股票名單(主要是小市值股票),其中有相當多的最近內部買入。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。